北美遗传性癌症检测市场，按测试类型（多面板集和单点基因测试）、诊断类型（活检、成像、实验室测试）、技术（测序、聚合酶链反应 (PCR)、微阵列）、疾病类型（遗传性乳腺癌和卵巢癌综合征、考登综合征、林奇综合征、遗传性白血病和血液系统恶性肿瘤综合征、家族性腺瘤性息肉病(FAP)、李-法美尼综合征、希佩尔-林道病、多发性内分泌肿瘤 (MEN) 综合征）、最终用户（医院、诊所、实验室、放射中心、诊断中心、其他）、分销渠道（直接招标、零售销售）、趋势和预测到 2029 年。
北美遗传性癌症检测市场分析与洞察
癌症是一种遗传性疾病，由控制细胞功能的基因发生某些突变引起，尤其影响细胞的生长和繁殖。遗传基因突变是造成大约 5-10% 的癌症的原因。研究人员发现，特定基因的突变与 50 多种遗传性癌症综合征有关，这些综合征通过某些癌症的发展影响人类。此外，约 5-10% 的乳腺癌病例与从父母遗传的基因突变有关。因此，癌症患病率的上升推动了遗传性癌症的稳步增长，从而推动了遗传性癌症检测市场的增长。此外，对非侵入性检测方法的需求增加以及对更高质量医疗保健和早期诊断的需求不断增长是市场增长的主要机会。此外，遗传性癌症检测过程中面临的道德挑战和市场参与者之间日益激烈的竞争是市场增长的关键挑战。
然而，严格的癌症诊断规定和与测试相关的高昂成本可能会阻碍市场的增长。
Data Bridge Market Research 分析，北美遗传性癌症检测市场预计到 2029 年将达到 55.9619 亿美元的价值，预测期内的复合年增长率为 13.3%。本市场报告还深入介绍了定价分析、专利分析和技术进步。
|
报告指标 |
细节 |
|
预测期 |
2022 至 2029 年 |
|
基准年 |
2021 |
|
历史岁月 |
2020（可定制至 2019 - 2015） |
|
定量单位 |
收入（百万美元）、销量（单位）、定价（美元） |
|
涵盖的领域 |
按测试类型（多组和单点基因测试）、诊断类型（活检、成像、实验室测试）、技术（测序、聚合酶链反应 (PCR)、微阵列）、疾病类型（遗传性乳腺癌和卵巢癌综合征、考登综合征、林奇综合征、遗传性白血病和血液系统恶性肿瘤综合征、家族性腺瘤性息肉病 (FAP)、李-法美尼综合征、希佩尔-林道病、多发性内分泌肿瘤 (MEN) 综合征）、最终用户（医院、诊所、实验室、放射中心、诊断中心、其他）、分销渠道（直接招标、零售）。 |
|
覆盖国家 |
美国、加拿大、墨西哥 |
|
涵盖的市场参与者 |
Invitae Corporation、Illumina, Inc.、Natera, Inc.、CENTOGENE NV、4baseCare、Biocartis、Fulgent Genetics、Ambry Genetics、BioReference、PerkinElmer Inc.、LifeLabs、Abbott、BIO-HELIX、Cepheid、Eurofins Scientific 等。 |
北美遗传性癌症检测市场定义
遗传性癌症是由遗传基因突变引起的任何癌症。某些基因的有害变异与癌症风险增加有关。基因检测可以估计一个人一生中患癌症的风险。这可以通过寻找基因、染色体或蛋白质的突变来实现。基因检测可用于多种类型的癌症。这些包括乳腺癌、卵巢癌、结肠癌、甲状腺癌、前列腺癌、胰腺癌、皮肤癌、肉瘤以及肾癌和胃癌。许多医学研究表明，5% 到 10% 的常见癌症被认为是遗传性的。进行基因测试以确定一个人是否携带有害的基因变异。这些测试还有助于确定尚未患癌症的家庭成员是否遗传了与已知具有癌症易感性替代方案的家庭成员相同的变异。
北美遗传性癌症检测市场动态
本节旨在了解市场驱动因素、优势、机遇、限制和挑战。下面将详细讨论所有这些内容：
驱动程序
- 遗传性癌症发病率上升
癌症是由细胞不受控制的生长引起的。癌症是由控制细胞生长和分裂的遗传信息（基因）发生有害变化（突变）引起的，这些变化会阻止细胞有效地发挥作用。
在遗传性癌症病例中，个体从父母一方遗传了突变的生长调节基因的副本，从另一方遗传了相同基因的工作副本。突变基因也称为“癌症易感基因”。由于这种癌症易感基因是遗传的，因此它存在于身体的每个细胞中，但该基因的工作副本使每个细胞正常运作。但是，如果突变破坏了细胞中基因的功能副本，细胞就会失去对其生长的控制并变成癌症。因此，继承癌症基因的个体在其一生中患上某些癌症的可能性要大得多。
因此，遗传性癌症发病率的上升增加了对遗传性癌症检测的需求，并可能成为北美遗传性癌症检测市场增长的驱动力。
- 老年人口增加
癌症可能是老年患者的疾病。在全球范围内，老年人口正在增加。老年人患遗传性癌症的风险更大。老年人口的增加可以为北美遗传性癌症检测市场提供更好的服务。它预计北美遗传性癌症检测市场的需求将激增。 人口老龄化正在导致人口结构的重新分配 ，这将影响医疗保健的未来。毫无疑问，癌症的风险会随着年龄的增长而呈指数级增长。
根据全球最大的完整家族结构和医学证实的癌症数据库，遗传性癌症（包括其发病率和相关风险）在 8-20 岁人群中，父母或兄弟姐妹患病且无亲属的人群的发病率大约是正常人群的两倍。小肠癌、睾丸癌、甲状腺癌和骨癌的风险是正常人群的五到八倍。
因此，老年人口癌症发病率的增加预计将成为北美遗传性癌症检测市场增长的一个驱动因素。
克制
- 遗传性癌症检测费用高昂
遗传性癌症检测采用技术高度先进的产品。这些产品的开发需要开发商进行严格的研究和开发。因此，程序和产品成本仍然很高，这相应地增加了检测成本。检测试剂盒价格昂贵，因为它们非常耗费资源，而且需要高薪医生、交通和昂贵的药物。
此外，检测程序也用于癌症检测。然而，此类程序非常昂贵，并且可能伴有并发症和更糟糕的长期结果。
因此，使用先进方式和技术产品进行癌症检测的高成本可能是北美遗传性癌症检测市场增长的主要制约因素。
机会
-
市场参与者的战略举措
北美遗传性癌症检测市场的崛起增加了对战略性商业理念的需求。它包括合作伙伴关系、业务扩展和其他发展。遗传性癌症治疗需求的激增显著增加了对诊断检测方法的需求。计划中的战略使市场参与者能够与组织的职能活动保持一致，以实现既定目标。它指导公司的讨论和决策，以确定实现目标所需的资源和预算，从而提高运营效率。
这些战略举措，例如主要市场参与者的产品发布、协议和业务扩展，将促进市场增长，并有望成为北美遗传性癌症检测市场的机会。这些战略举措有望促进增长并改善公司的产品组合，最终带来更多收入。因此，市场参与者的这些战略举措有望成为北美遗传性癌症检测市场增长的机会。
挑战
- 遗传性癌症检测面临的伦理挑战
在遗传性癌症基因检测过程中，一个重大的道德障碍是医疗专业人员缺乏有关基因检测的基本知识，并且对解释家族疾病模式缺乏信心。医疗服务提供者面临的挑战是提供足够的信息来支持患者的决策，并提供证据来支持他们可能提出的任何建议背后的理由。
缺乏报销会给医疗带来经济障碍。遗传性癌症风险评估和咨询的过程非常耗时，而且目前还不清楚如何最好地记录和计费这项服务。肿瘤学家经常被迫应对基因检测的潜在不确定的报销环境，第三方付款人的报销政策各不相同。
遗传性癌症基因检测引发了道德问题，而这些问题无法由患者或其家人解决。伦理、文化和宗教等各方面的问题不应成为遗传性癌症检测的障碍。所有这些都是需要解决的问题。因此，遗传性癌症检测过程中的道德挑战预计将对市场增长构成挑战。
后 COVID-19 对北美遗传性癌症检测市场的影响
过去 18 个月，全球许多行业都处于不利地位。这可能是由于全球各地的工厂采取了各种预防措施，例如停工和其他限制，导致其工业和供应链流程遭受重大中断。北美遗传性癌症检测市场也是如此。此外，由于大多数人的整体财务状况受到繁荣的严重影响，人们现在有更多机会从预算中排除非必要开支，因此消费需求随之下降。预计上述因素将在预测期内加重北美遗传性癌症检测市场的收入利润。
制造商正在制定各种战略决策，以在新冠疫情后实现复苏。参与者正在进行多项研发活动、产品发布和战略合作，以改进移植诊断市场所涉及的技术和测试结果。
近期发展
- 2022 年 7 月，Helio Genomics 及其业务合作伙伴 Fulgent Genetics (FLGT) 宣布，美国医学会 (AMA) 为 HelioLiver 发布了新的 I 类现行程序术语 (CPT) 专有实验室分析代码，并在美国更广泛地采用先进的创新肝癌监测测试，这有助于该公司扩大其产品组合。
北美遗传性癌症检测市场范围
北美遗传性癌症检测市场细分为检测类型、诊断类型、技术、疾病类型、最终用户和分销渠道。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。
按测试类型
- 多面板测试
- 单点基因测试
根据测试类型，北美遗传性癌症检测市场分为多面板测试和单点基因测试。
按诊断类型
- 活检
- 成像
- 实验室测试
根据诊断类型，北美遗传性癌症检测市场分为活检、影像和实验室测试。
按技术分类
- 测序
- 聚合酶链式反应（PCR）
- 微阵列
根据技术，北美遗传性癌症检测市场分为测序、聚合酶链反应（PCR）和微阵列。
按疾病类型
- 遗传性乳腺癌和卵巢癌综合征
- 考登综合症
- 林奇综合症
- 遗传性白血病和血液系统恶性肿瘤综合征
- 家族性腺瘤性息肉病 (FAP)
- 李法美尼症候群
- 希佩尔-林道病
- 多发性内分泌肿瘤（男性）综合征
根据疾病类型，北美遗传性癌症检测市场细分为遗传性乳腺癌和卵巢癌综合征、考登综合征、林奇综合征、遗传性白血病和血液系统恶性肿瘤综合征、家族性腺瘤性息肉病 (FAP)、李-法美尼综合征、沃尔-希佩尔-林道病、多发性内分泌肿瘤 (MEN) 综合征。
由最终用户
根据最终用户，北美遗传性癌症检测市场分为医院、诊所、实验室、放射中心、诊断中心和其他。
按分销渠道
- 直接招标
- 零售销售
根据分销渠道，北美遗传癌症检测市场分为直接招标、零售。
北美遗传性癌症检测市场区域分析/见解
对北美遗传性癌症检测市场进行了分析，并提供了市场规模信息，包括检测类型、诊断类型、技术、疾病类型、最终用户和分销渠道。
本市场报告涵盖的国家包括美国、加拿大和墨西哥。
- 2022 年，美国将占据主导地位，因为美国是 GDP 最高的最大的消费市场，拥有关键的市场参与者，并且拥有用于癌症诊断的最新先进技术和发明。
报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外，在对国家数据进行预测分析时，还考虑了北美品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀少竞争而面临的挑战，以及销售渠道的影响。
竞争格局和北美遗传性癌症检测市场份额分析
北美遗传性癌症检测市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对北美遗传性癌症检测市场的关注有关。
北美遗传性癌症检测市场的一些主要参与者包括 Invitae Corporation、Illumina, Inc.、Natera, Inc.、CENTOGENE NV、4baseCare、Biocartis、Fulgent Genetics、Ambry Genetics、BioReference、PerkinElmer Inc.、LifeLabs、Abbott、BIO-HELIX、Cepheid、Eurofins Scientific 等。
研究方法：北美遗传性癌症检测市场
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析以及主要（行业专家）验证。除此之外，数据模型还包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、公司市场份额分析、测量标准、北美与地区以及供应商份额分析。如有进一步询问，请要求分析师致电。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA HEREDITARY CANCER TESTING MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USER COVERAGE GRID
2.8 SOURCE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 NORTH AMERICA HEREDITARY CANCER TESTING MARKET: REGULATIONS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING INCIDENCE OF HEREDITARY CANCER
6.1.2 INCREASE IN THE GERIATRIC POPULATION
6.1.3 RISING HEALTHCARE SPENDING
6.1.4 INCREASE IN AWARENESS ABOUT CANCER TESTING
6.2 RESTRAINTS
6.2.1 HIGH COST OF HEREDITARY CANCER TESTING
6.2.2 LACK OF SKILLED PROFESSIONALS
6.3 OPPORTUNITIES
6.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS
6.3.2 INCREASED DEMAND FOR NON-INVASIVE TESTING METHODS
6.3.3 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE AND EARLY DIAGNOSIS
6.3.4 TECHNOLOGICAL DEVELOPMENTS IN HEREDITARY CANCER TESTING PROCEDURES
6.4 CHALLENGES
6.4.1 ETHICAL CHALLENGES FACED DURING HEREDITARY CANCER TESTING
6.4.2 RISING COMPETITION AMONG MARKET PLAYERS
7 NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE
7.1 OVERVIEW
7.2 MULTI PANEL TEST
7.3 SINGLE-SITE GENETIC TEST
8 NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE
8.1 OVERVIEW
8.2 BIOPSY
8.2.1 NEEDLE BIOPSIES
8.2.2 ENDOSCOPIC BIOPSIES
8.2.3 LAPAROSCOPIC, THORACOSCOPIC, AND MEDIASTINOSCOPIC BIOPSY
8.2.4 LAPAROTOMY AND THORACOTOMY
8.2.5 OTHERS
8.3 IMAGING
8.3.1 MAGNETIC RESONANCE IMAGING (MRI)
8.3.2 COMPUTED TOMOGRAPHY (CT) SCAN
8.3.3 POSITRON EMISSION TOMOGRAPHY (PET) SCAN
8.3.4 NUCLEAR SCAN
8.3.5 ULTRASOUND
8.3.6 X-RAYS
8.4 LAB TESTS
8.4.1 BLOOD
8.4.2 URINE
8.4.3 OTHERS
9 NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY
9.1 OVERVIEW
9.2 POLYMERASE CHAIN REACTION (PCR)
9.3 SEQUENCING
9.4 MICRO ARRAY
10 NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE
10.1 OVERVIEW
10.2 HEREDITARY BREAST & OVARIAN CANCER SYNDROME
10.3 COWDEN SYNDROME
10.4 LYNCH SYNDROME
10.5 HEREDITARY LEUKEMIA AND HEMATOLOGIC MALIGNANCIES SYNDROME
10.6 FAMILIAL ADENOMATOUS POLYPOSIS (FAP)
10.7 LI-FRAUMENI SYNDROME
10.8 VON HIPPEL-LINDAU DISEASE
10.9 MULTIPLE ENDOCRINE NEOPLASIAS (MEN) SYNDROME
11 NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.3 CLINICS
11.4 DIAGNOSTIC CENTERS
11.5 RADIOLOGY CENTERS
11.6 LABORATORIES
11.7 OTHERS
12 NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDER
12.3 RETAIL SALES
13 NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY REGION
13.1 NORTH AMERICA
13.1.1 U.S.
13.1.2 CANADA
13.1.3 MEXICO
14 NORTH AMERICA HEREDITARY CANCER TESTING MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 ABBOTT
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENTS
16.2 ILLUMINA, INC. (2021)
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENTS
16.3 PERKINELMER INC. (2021)
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 LIFELABS GENETICS
16.4.1 COMPANY SNAPSHOT
16.4.2 COMPANY SHARE ANALYSIS
16.4.3 PRODUCT PORTFOLIO
16.4.4 RECENT DEVELOPMENTS
16.5 EUROFINS SCIENTIFIC (2021)
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 COMPANY SHARE ANALYSIS
16.5.4 PRODUCT PORTFOLIO
16.5.5 RECENT DEVELOPMENT
16.6 AMBRY GENETICS
16.6.1 COMPANY SNAPSHOT
16.6.2 REVENUE ANALYSIS
16.6.3 PRODUCT PORTFOLIO
16.6.4 RECENT DEVELOPMENTS
16.7 BIOCARTIS
16.7.1 COMPANY SNAPSHOT
16.7.2 REVENUE ANALYSIS
16.7.3 PRODUCT PORTFOLIO
16.7.4 RECENT DEVELOPMENTS
16.8 BIO-HELIX
16.8.1 COMPANY SNAPSHOT
16.8.2 PRODUCT PORTFOLIO
16.8.3 RECENT DEVELOPMENTS
16.9 BIOREFERENCE (A SUBSIDIARY OF OPKO HEALTH, INC.) (2021)
16.9.1 COMPANY SNAPSHOT
16.9.2 REVENUE ANALYSIS
16.9.3 PRODUCT PORTFOLIO
16.9.4 RECENT DEVELOPMENT
16.1 CENTOGENE N.V. (2021)
16.10.1 COMPANY SNAPSHOT
16.10.2 REVENUE ANALYSIS
16.10.3 PRODUCT PORTFOLIO
16.10.4 RECENT DEVELOPMENT
16.11 CEPHEID
16.11.1 COMPANY SNAPSHOT
16.11.2 PRODUCT PORTFOLIO
16.11.3 RECENT DEVELOPMENT
16.12 FULGENT GENETICS
16.12.1 COMPANY SNAPSHOT
16.12.2 REVENUE ANALYSIS
16.12.3 PRODUCT PORTFOLIO
16.12.4 RECENT DEVELOPMENT
16.13 INVITAE CORPORATION
16.13.1 COMPANY SNAPSHOT
16.13.2 REVENUE ANALYSIS
16.13.3 PRODUCT PORTFOLIO
16.13.4 RECENT DEVELOPMENT
16.14 NATERA, INC. (2021)
16.14.1 COMPANY SNAPSHOT
16.14.2 REVENUE ANALYSIS
16.14.3 PRODUCT PORTFOLIO
16.14.4 RECENT DEVELOPMENTS
16.15 4BASECARE.
16.15.1 COMPANY SNAPSHOT
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENTS
17 QUESTIONNAIRE
18 RELATED REPORTS
表格列表
TABLE 1 NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 2 NORTH AMERICA MULTI PANEL TEST IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 NORTH AMERICA SINGLE-SITE GENETIC TEST IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 5 NORTH AMERICA BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 NORTH AMERICA BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 7 NORTH AMERICA IMAGING IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 NORTH AMERICA IMAGING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 9 NORTH AMERICA LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 NORTH AMERICA LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 11 NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 12 NORTH AMERICA POLYMERASE CHAIN REACTION (PCR) IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 NORTH AMERICA SEQUENCING IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 NORTH AMERICA MICROARRAY IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 16 NORTH AMERICA HEREDITARY BREAST & OVARIAN CANCER SYNDROME IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 NORTH AMERICA COWDEN SYNDROME IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 NORTH AMERICA LYNCH SYNDROME IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 NORTH AMERICA HEREDITARY LEUKEMIA AND HEMATOLOGIC MALIGNANCIES SYNDROME IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 NORTH AMERICA FAMILIAL ADENOMATOUS POLYPOSIS (FAP) IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 NORTH AMERICA LI-FRAUMENI SYNDROME IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 NORTH AMERICA VON HIPPEL-LINDAU DISEASE IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 NORTH AMERICA MULTIPLE ENDOCRINE NEOPLASIAS (MEN) SYNDROME IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 25 NORTH AMERICA HOSPITALS CENTERS IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 NORTH AMERICA CLINICS IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 NORTH AMERICA DIAGNOSTIC CENTERS IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 NORTH AMERICA RADIOLOGY CENTERS IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 NORTH AMERICA LABORATORIES IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 NORTH AMERICA OTHERS IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 32 NORTH AMERICA DIRECT TENDER IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 NORTH AMERICA RETAIL SALES IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 35 NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 36 NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 37 NORTH AMERICA BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 38 NORTH AMERICA IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 39 NORTH AMERICA LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 40 NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 41 NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 42 NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 43 NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 44 U.S. HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 45 U.S. HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 46 U.S. HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 ASP (USD)
TABLE 47 U.S. HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 48 U.S. BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 49 U.S. IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 50 U.S. LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 51 U.S. HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 52 U.S. HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 53 U.S. HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 54 U.S. HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 55 CANADA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 56 CANADA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 57 CANADA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 ASP (USD)
TABLE 58 CANADA HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 59 CANADA BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 60 CANADA IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 61 CANADA LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 62 CANADA HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 63 CANADA HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 64 CANADA HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 65 CANADA HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 66 MEXICO HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 67 MEXICO HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 68 MEXICO HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 ASP (USD)
TABLE 69 MEXICO HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 70 MEXICO BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 71 MEXICO IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 72 MEXICO LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)
TABLE 73 MEXICO HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 74 MEXICO HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 75 MEXICO HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 76 MEXICO HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
图片列表
FIGURE 1 NORTH AMERICA HEREDITARY CANCER TESTING MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA HEREDITARY CANCER TESTING MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA HEREDITARY CANCER TESTING MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA HEREDITARY CANCER TESTING MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA HEREDITARY CANCER TESTING MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA HEREDITARY CANCER TESTING MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA HEREDITARY CANCER TESTING MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 NORTH AMERICA HEREDITARY CANCER TESTING MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA HEREDITARY CANCER TESTING MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA HEREDITARY CANCER TESTING MARKET: SEGMENTATION
FIGURE 11 EXPANDING REPRODUCTIVE GENETIC HEALTH SPACE IS EXPECTED TO DRIVE THE NORTH AMERICA HEREDITARY CANCER TESTING MARKET IN THE FORECAST PERIOD
FIGURE 12 MULTI PANEL TEST SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA HEREDITARY CANCER TESTING MARKET IN 2022 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA HEREDITARY CANCER TESTING MARKET
FIGURE 14 NORTH AMERICA HEREDITARY CANCER TESTING MARKET: BY TEST TYPE, 2021
FIGURE 15 NORTH AMERICA HEREDITARY CANCER TESTING MARKET: BY TEST TYPE, 2022-2029 (USD MILLION)
FIGURE 16 NORTH AMERICA HEREDITARY CANCER TESTING MARKET: BY TEST TYPE, CAGR (2022-2029)
FIGURE 17 NORTH AMERICA HEREDITARY CANCER TESTING MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 18 NORTH AMERICA HEREDITARY CANCER TESTING MARKET: BY DIAGNOSIS TYPE, 2021
FIGURE 19 NORTH AMERICA HEREDITARY CANCER TESTING MARKET: BY DIAGNOSIS TYPE, 2022-2029 (USD MILLION)
FIGURE 20 NORTH AMERICA HEREDITARY CANCER TESTING MARKET: BY DIAGNOSIS TYPE, CAGR (2022-2029)
FIGURE 21 NORTH AMERICA HEREDITARY CANCER TESTING MARKET: BY DIAGNOSIS TYPE, LIFELINE CURVE
FIGURE 22 NORTH AMERICA HEREDITARY CANCER TESTING MARKET : BY TECHNOLOGY, 2021
FIGURE 23 NORTH AMERICA HEREDITARY CANCER TESTING MARKET : BY TECHNOLOGY, 2020-2029 (USD MILLION)
FIGURE 24 NORTH AMERICA HEREDITARY CANCER TESTING MARKET : BY TECHNOLOGY, CAGR (2022-2029)
FIGURE 25 NORTH AMERICA HEREDITARY CANCER TESTING MARKET : BY TECHNOLOGY, LIFELINE CURVE
FIGURE 26 NORTH AMERICA HEREDITARY CANCER TESTING MARKET: BY DISEASE TYPE, 2021
FIGURE 27 NORTH AMERICA HEREDITARY CANCER TESTING MARKET: BY DISEASE TYPE, 2022-2029 (USD MILLION)
FIGURE 28 NORTH AMERICA HEREDITARY CANCER TESTING MARKET: BY DISEASE TYPE, CAGR (2022-2029)
FIGURE 29 NORTH AMERICA HEREDITARY CANCER TESTING MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 30 NORTH AMERICA HEREDITARY CANCER TESTING MARKET : BY END USER, 2021
FIGURE 31 NORTH AMERICA HEREDITARY CANCER TESTING MARKET : BY END USER, 2020-2029 (USD MILLION)
FIGURE 32 NORTH AMERICA HEREDITARY CANCER TESTING MARKET : BY END USER, CAGR (2022-2029)
FIGURE 33 NORTH AMERICA HEREDITARY CANCER TESTING MARKET : BY END USER, LIFELINE CURVE
FIGURE 34 NORTH AMERICA HEREDITARY CANCER TESTING MARKET : BY DISTRIBUTION CHANNEL, 2021
FIGURE 35 NORTH AMERICA HEREDITARY CANCER TESTING MARKET : BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
FIGURE 36 NORTH AMERICA HEREDITARY CANCER TESTING MARKET : BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 37 NORTH AMERICA HEREDITARY CANCER TESTING MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 38 NORTH AMERICA HEREDITARY CANCER TESTING MARKET: SNAPSHOT (2021)
FIGURE 39 NORTH AMERICA HEREDITARY CANCER TESTING MARKET: BY COUNTRY (2021)
FIGURE 40 NORTH AMERICA HEREDITARY CANCER TESTING MARKET: BY COUNTRY (2022 & 2029)
FIGURE 41 NORTH AMERICA HEREDITARY CANCER TESTING MARKET: BY COUNTRY (2021 & 2029)
FIGURE 42 NORTH AMERICA HEREDITARY CANCER TESTING MARKET: BY TEST TYPE (2022-2029)
FIGURE 43 NORTH AMERICA HEREDITARY CANCER TESTING MARKET: COMPANY SHARE 2021 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
